 | LET’S GO DESIGN: Episode #5
In this episode of SolidWorks’ interactive web series, Jeremy moves closer to the final design of our Hot Rod Baby Buggy and also hot-wires the golf cart motor to show how the aluminum tracks perform flawlessly. Watch at LetsGoDesign.tv. |
 - Experts develop close embryonic clones of patients with diabetes
Scientists at the New York Stem Cell Foundation Laboratory were able to develop 13 early-stage human embryos that are close copies of patients with diabetes after deriving DNA-carrying nuclei from the patients' skin cells and adding them to unfertilized human eggs, which later on reprogrammed the cells into blastocysts. They also reported in the journal Nature that they were able to turn master stem cells, which are reprogrammed skin cells by the eggs, into nerves and other types of cells. Although the embryos aren't considered viable because of the extra set of chromosomes, the technique might pave the way for the development of tailor-made stem cells for use in the treatment of serious conditions. The Wall Street Journal (tiered subscription model) (10/6)        | Kickstart your business’ marketing with FedEx Office! Save big on posters, postcards and brochures, with up to 40% off on select print products. Go to FedEx Office to take advantage of the Look Good On Paper Print Sale to get discounts on all your business printing needs. |
  - Sanofi Pasteur builds major manufacturing facility for vaccines
Sanofi's vaccine division, Sanofi Pasteur, is building a state-of-the-art plant in India as part of a 2015 goal to achieve 40% of sales from emerging markets. The facility, touted as the largest in Asia, will be fully operational in October 2012. Sanofi invested $300 million for capacity expansion after buying India's Shantha Biotechnics in 2009, said CEO Chris Viehbacher. Business Standard (India) (10/6) - FDA accepts Merck and Ariad's cancer drug for standard review
The FDA accepted for standard review Merck & Co. and Ariad Pharmaceuticals' ridaforolimus, a drug candidate for metastatic soft-tissue or bone sarcomas. The drug, submitted in August for EU approval, works by inhibiting the mTOR protein, which plays a role in the growth and survival of cells. Reuters (10/5)  | With in-depth industry experience and expertise, GE Capital, Healthcare Financial Services’ dedicated Life Science Finance team has worked with more than 500 companies and provided over $2.5 billion in financing to the market. Click here to find out more and take our online poll. | | Industry Deals |  |  | | - Agios extends drug-development deal with Celgene
Agios Pharmaceuticals agreed to extend by one year an exclusive, three-year partnership with Celgene to develop cancer-metabolism treatments. Under the extended agreement, Agios will receive $20 million and give Celgene an option to further extend the partnership. Reuters (10/5), Xconomy/Boston (10/5)  | Earn 2X rewards points on advertising costs with The New Business Gold Rewards Card from American Express OPEN. Designed to earn Membership Rewards® points faster:
• 3X points on airfare
• 2X points on advertising, gas, shipping
• 1X points on everything else
• For a limited time, 50K bonus points when you spend $10K your first 5 months
LEARN MORE AND APPLY |
 
| Industrial & Environmental | | | | - Survey: Employment in Calif.'s biotech sector grew 632% in 5 years
Employment in California's "industrial biotechnology" sector, including biofuel businesses, increased 632% over the past five years, according to a poll by industry groups BayBio and BIOCOM. Policymakers should consider providing tax breaks and other incentives to keep California an attractive place for biotech companies, supporters said. "It is important for California's policymakers and educational institutions to be aware of the challenges and opportunities facing these emerging companies in order to bolster the strength of California's biotechnology industry and help bring innovative, environmentally advantageous products to market," said BayBio President and CEO Gail Maderis. American City Business Journals/San Francisco/Biotech SF blog (10/5) | News from BIO | | | | - BIO argues for a 21st century FDA
In this issue of FDLI's Food and Drug Law Policy Forum (Volume 1, Issue 18), James C. Greenwood, president and CEO of the Biotechnology Industry Organization (BIO), answers this provocative question: Can a 21st Century FDA Accelerate Biotech Innovation to Cure Disease and Save Lives? Greenwood argues that Congress needs to elevate the agency to independent status (like EPA); that FDA must advance regulatory science and innovation through a chief innovation officer; and that FDA should enable modernized patient-centric clinical development, all to make FDA a truly effective regulatory agency. Read the article here.
| SmartQuote | | | |  | A guilty conscience is the mother of invention."
--Carolyn Wells,
American writer and poet  |
| | This SmartBrief was created for jmabs1@gmail.com
| | | Read more at SmartBrief.com | | A powerful website for SmartBrief readers including: | | | | | | | | | | Recent BIO SmartBrief Issues: - Wednesday, October 05, 2011
- Tuesday, October 04, 2011
- Monday, October 03, 2011
- Friday, September 30, 2011
- Thursday, September 29, 2011
| | | Lead Editor: Adam Gaub
Mailing Address:
SmartBrief, Inc.®, 1100 H ST NW, Suite 1000, Washington, DC 20005 | | | | | | © 1999-2011 SmartBrief, Inc.® Legal Information |
|
No comments:
Post a Comment